Non-small cell lung cancer

News

FDA grants fast review for AstraZeneca's Tagrisso in early-s...

The FDA has granted a fast review for AstraZeneca’s Tagrisso oncology drug in certain patients with early-stage lung cancer.

News

New data reinforce Keytruda's dominance in first-line lung c...

Five-year data with Merck & Co’s Keytruda showing that it doubles survival should help the drug fend off a growing number of contenders to the first-line non-small cell lung cancer (NSC

News

AstraZeneca's (AZ) Tagrisso (osimertinib)

Price cut wins NICE OK for AZ’s Tagrisso in untreated lung c...

UK cost-effectiveness watchdog NICE has changed its stance on AstraZeneca’s Tagrisso as a first-line therapy for non-small cell lung cancer (NSCLC) after an improved “commercial arrangement

News

FDA starts quick review of Merck’s MET-targeting lung cancer...

Merck KGaA could be looking at an early 2021 approval for its MET inhibitor tepotinib in lung cancer from the FDA after the US regulator started a priority review of the drug,

News

Latecomer Lilly throws cash at Innovent PD-1 partnership

Eli Lilly has doubled down on its partnership with Chia’s Innovent with a licensing deal for ex-China rights to Tyvyt, their PD-1 inhibitor, which some analysts think may be la

News

"Tokyo, Japan - May 11, 2012: Pfizer building on May 11, 2012 in Tokyo. Pfizer is one of largest pharmaceutical companies worldwide with tremendous revenue $67.4 bn USD for 2011. It exists since 1849."

Will new data make Pfizer's Lorbrena a ‘no-brainer’ in early...

Pfizer has taken a big step towards positioning Lorbrena as a worthy heir to its big-selling Xalkori drug in lung cancer, after beating its parent in a phase 3 trial.

FDA grants fast review for AstraZeneca's Tagrisso in early-s...

New data reinforce Keytruda's dominance in first-line lung c...

Price cut wins NICE OK for AZ’s Tagrisso in untreated lung c...

FDA starts quick review of Merck’s MET-targeting lung cancer...

Latecomer Lilly throws cash at Innovent PD-1 partnership

Will new data make Pfizer's Lorbrena a ‘no-brainer’ in early...

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Non-small cell lung cancer

Editor's Picks